Management of premenopausal women with primary breast cancer

British Journal of Surgery

Volumn 83, Issue 9, 1996, Pages 1256-1257

  Woodman, C B J ^a   Singleton, J ^a   Coyne, J ^b   Baildam, A ^b  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b WITHINGTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PATIENT CARE; PREMENOPAUSE; PRIORITY JOURNAL;

EID: 0029782883     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1002/bjs.1800830924     Document Type: Article

References (5)

1. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 1992; 339: 1-15, 71-84.
2. Veronesi U, Galimberti V, Zurrida S et al. Prognostic-significance of number and level of axillary node metastases in breast cancer. Breast 1193; 2: 224-8.
3. Douglas E, Merkel DE, Osborne CK. Prognostic factors in breast cancer. Haematology/Oncology Clinics of North America 1989; 3: 641-52.
4. Miller WR, Ellis IO, Sainsbury JRC, Dixon JM. Prognostic factors. ABC of breast diseases. BMJ 1994; 309: 1573-6.
5. Richards MA, Smith IE, Dixon JM. Role of systemic treatment for primary operable breast cancer. BMJ 1994; 309: 1363-5.